Morning

About Us

Ironshore Pharmaceuticals Inc. is a US-based pharmaceutical company whose mission is to commercialize innovative, patient-centric treatment options to improve the lives of patients and caregivers.

What We Do


Based in Durham, North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US. Ironshore Pharmaceuticals Inc. was founded in 2015 and is a wholly owned subsidiary of Toronto-based Highland Therapeutics, Inc.

Ironshore Pharmaceuticals Inc.

Controlled Release

 
430 Davis Drive, Suite 250
Durham, NC 27560
United States

Controlled Release

 
2370 State Route 70 West, Suite 309
Cherry Hill, NJ 08002
United States

Leadership


W. Scott Evangelista
President &
Chief Operating Officer

Peter Lammers
Senior Vice President, Commercial

Dr. Randy Sallee
Chief Medical Officer

Lewis E. Warrington, MD
Vice President, Medical Affairs

Tom McHugh
Senior Vice President, Finance

Terry Lynn Crandall
General Counsel &
Chief Compliance Office

Don Allen
Senior Vice President, Manufacturing, Quality & Supply

Colin Boatwright
Chief Information Officer

Scott Evangelista

Scott Evangelista is President and Chief Operating Officer of Ironshore Pharmaceuticals and is responsible for building and leading the team to support the launch of JORNAY PM™ in the US.

Scott most recently served as President of Integrated Healthcare Services at IQVIA, working with biopharmaceutical and healthcare customers to develop real-world evidence and commercialization solutions. Prior to joining IQVIA, Scott was a principal in the life sciences practice at Deloitte Consulting LLP, working with a variety of biopharmaceutical customers across a diverse spectrum of commercial operations where he provided strategic consulting, business development support and management guidance. Before joining Deloitte, Scott was the founder and managing partner of the Swiftwater Group, a management consulting firm that helped biopharmaceutical clients develop and implement successful lifecycle plans and improve product performance at all stages.

Scott earned his bachelor’s degree in finance and a master’s degree in management information systems from Boston University.

Peter Lammers

Peter Lammers is Senior Vice President, Commercial of Ironshore Pharmaceuticals. In this role, Peter is responsible for leading the team to support all aspects of the launch and commercialization of JORNAY PM™ in the US including sales, marketing, market access and commercial operations.

Peter has over 30 years of Pharmaceutical and Life Sciences experience. Peter most recently served as Vice President of New Offer Development at IQVIA, responsible for leading a team creating new integrated commercial capabilities to address life sciences and medical devices clients need to improve execution and engagement with Providers and Patients. Prior to joining IQVIA, he held leadership roles in consulting and life sciences technology companies. Peter was at GlaxoSmithKline for over 25 years where he served in multiple sales, marketing and R&D roles of increasing leadership responsibilities.

Peter earned his bachelor’s degree in business and chemistry and completed executive master’s programs at Fuqua and Wharton Schools of Business.

Dr. Randy Sallee

Dr. Randy Sallee serves as the Company's Chief Medical Officer. Dr. Sallee has extensive research experience in both preclinical and clinical drug development. His administrative posts have included positions of Vice Chairman of the Department and Division Chief of Child Psychiatry at Cincinnati Children's Hospital Medical Center. As a leader in pediatric clinical pharmacology, Dr. Sallee founded the Pediatric Pharmacology Research Unit (PPRU) at Cincinnati Children's Hospital and is credited with supporting pediatric labeling for well over 50 marketed drugs in a wide range the therapeuticareas. Dr. Sallee has expertise in Orphan Drug Development, and has worked to bring new therapies to Prader Willi, Tourette Syndrome, Frontotemporal Dementia and Rett Syndrome.

Dr. Sallee is the author of over one hundred publications in refereed scientific journals whose research has been funded by the National Institutes of Health since 1990.

Dr. Sallee holds doctorates in pharmacology (University of Pittsburgh) and medicine (SIU School of Medicine) and is Board Certified in Psychiatry, Child Psychiatry and Clinical Pharmacology.

Lewis E. Warrington, MD

Lewis E. Warrington, MD, is Vice President and Head of Medical Affairs responsible for developing and managing medical strategy and supportive tactics for commercialized brands as well as all other Medical Affairs activities including Field Medical.

Lewis most recently served as the Medical Affairs Strategic Lead at Merck responsible for the development of medical strategy for CNS and immunologic products. Prior to his time at Merck, Lewis was VP and Head of the CNS Medical Unit at Novartis with responsibility for various CNS products in ADHD, schizophrenia, and Alzheimer’s Disease. Before joining Novartis, Lewis was a Senior Medical Director in Medical Affairs at Sanofi responsible for commercialized and pipeline insomnia and depression products. Prior to Sanofi, Lewis began his pharmaceutical career as a Medical Director at Pfizer working in the schizophrenia disease area.

Lewis earned his medical degree from East Carolina University School of Medicine. He completed residency training in General Adult Psychiatry at the University of Virginia and fellowship training in Child and Adolescent Psychiatry at the University of Florida. He also completed a Postdoctoral Fellowship in Neuropsychopharmacology at Mayo Clinic.

Tom McHugh

Tom McHugh is Senior Vice President of Finance of Ironshore Pharmaceuticals and leads the Finance, Accounting and Treasury functions to support the launch of JORNAY PM™ in the U.S.

Tom most recently served as Chief Financial Officer and Treasurer at Lumara Health, a specialty pharmaceutical company that focused on maternal fetal medicine and obstetrics/gynecology. Prior to joining Lumara, Tom was a Managing Director and Global Controller at BearingPoint, a global consultancy. Before joining BearingPoint, he was the Chief Financial Officer at Huttig Building Products, a publicly traded distributor residential building products.

Tom earned his bachelor’s degree in finance from Bentley University and a master’s degree in accounting from Northeastern University.

Terry Lynn Crandall

Terry Crandall is General Counsel and Chief Compliance Officer of Ironshore Pharmaceuticals, responsible for the Company's risk management framework and advising the Company and its employees with respect to legal issues relevant to commercializing prescription medicines in the United States.

Terry served as a corporate attorney for GlaxoSmithKline for more than 13 years, and, in 2009, moved into ViiV Healthcare, a joint venture between GSK, Pfizer, and Shionogi, focusing on development and marketing of HIV medicines, as General Counsel and Chief Compliance Officer. In 2017, Terry left ViiV Healthcare and opened her own consulting business, providing legal and regulatory support to a number of pharma companies across the nation, including Ironshore.

Terry earned her law degree from the University of North Carolina, Chapel Hill, and holds Bachelors of Arts degrees in English and Psychology from Bucknell University. Terry is licensed to practice law in Illinois and North Carolina.

Don Allen

Don Allen is a seasoned executive within the pharmaceutical industry who has led manufacturing and supply chain operations across a variety of organizations and technologies. He has 35 years of plant operations and engineering experience including areas of API processing, small volume parental, solid and semi-solid dosage form manufacturing and as well as other specialty dosage form manufacturing including medicated gum, aerosol and transdermal patch manufacturing.

Don has led organizations at several brand, generic and specialty pharmaceutical companies across multiple manufacturing sites. He had responsibility for implementation of ERP systems across several different platforms, and he has formed and led Operational Excellence programs with roots in continuous improvement and lean manufacturing.

Done has a B.S. in Chemical Engineering from Purdue University and an MBA from the Quinlan School of Business at Loyola University Chicago.

Colin Boatwright

Colin is the Chief Information Officer of Ironshore Pharmaceuticals and is responsible for the IT strategy and ensuring all systems necessary to support operations and objectives are in place. His goal is to ensure technology adds the maximum value to help with the success of Ironshore's products.

Most recently, Colin was Vice President of TechOps at IQVIA where he ran the global technology aspects of the world's largest Contract Sales Organization. In that role he oversaw the development and implementation of operational systems for medical reps, medical science liaisons, nurse educators, and various roles support medical affairs. Additionally, he ran the organization’s patient support platforms. Prior to joining IQVIA, Colin held various C-level positions in several start-ups.

Colin earned his bachelor’s degree in mass communication from North Carolina State University.